3名Apellis内部人出售了107K美元股票,收入丰厚,股票不断上涨。 Three Apellis insiders sold $107K in stock Jan. 20 amid strong earnings and rising shares.

2026年1月20日,三名Apellis制药公司内幕人士Nur Nicholson、James George Chopas和David Watson共出售5 404股股票,每股平均价格19.79美元,共计约106 945美元。 On January 20, 2026, three Apellis Pharmaceuticals insiders—Nur Nicholson, James George Chopas, and David Watson—sold a combined total of 5,404 shares at an average price of $19.79 per share, totaling approximately $106,945. 这些交易在证交会档案中披露,减少了其所有权股份,Nicholson持有的股份下降到78 843股,Watson持有的股份下降到96 363股。 The transactions, disclosed in SEC filings, reduced their ownership stakes, with Nicholson’s holding dropping to 78,843 shares and Watson’s to 96,363. 该公司的股票在1月21日以20.95美元关闭,增加了0.48美元,交易额高于平均水平。 The company’s stock closed at $20.95 on January 21, up $0.48, with above-average trading volume. Apellis于10月30日报告Q3收入强劲, Apellis reported strong Q3 earnings on October 30, posting $1.67 EPS, surpassing estimates by $0.64, and recording a 133% year-over-year revenue increase. 该公司以罕见疾病疗法为重点,市场上限为26.5亿美元,协商一致的“Moderate Buy”评级为33.53美元。 The company, focused on rare disease therapies, has a market cap of $2.65 billion and a consensus “Moderate Buy” rating with a target of $33.53.